JUPITER, Fla., Oct. 22, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today ...
A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks ...
JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the U ...
MT-125, a selective inhibitor of non-muscle myosin II, targets glioblastoma's tumor proliferation and resistance mechanisms. The FDA's fast track designation aims to expedite MT-125's development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results